Medicare Enrolled

Dr. Roberto Pancorbo, MD

Rheumatology · Weston, FL
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
2950 CLEVELAND CLINIC BLVD, Weston, FL 33331
9546595000
In practice since 2006 (19 years)
NPI: 1730293911 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Pancorbo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Pancorbo? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Pancorbo

Dr. Roberto Pancorbo is a rheumatology specialist in Weston, FL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Pancorbo performed 91,729 Medicare services across 3,162 unique beneficiaries.

Between the years covered by Open Payments, Dr. Pancorbo received a total of $1,958 from 20 pharmaceutical and/or device companies across 107 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Pancorbo is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 27% volume in FL $1,958 industry payments

Florida License Status

FL DOH · MQA
1
Active license
None
Board action on record
0
Recent admin complaints
Profession License # Status Expires Board Action
Medical Doctor 111026 Clear January 31, 2028
Data from Florida Department of Health Medical Quality Assurance. License records are public under Chapter 119, Florida Statutes. Verify directly on FL DOH →

Medicare Practice Summary

Medicare Utilization ↗
91,729
Medicare services
Top 27% in FL for rheumatology
3,162
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4,828 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Tocilizumab injection (Actemra) 48,480 $5 $10
Golimumab infusion (Simponi Aria) 13,300 $11 $41
Abatacept infusion (Orencia) 12,500 $32 $106
Denosumab injection (Prolia/Xgeva) 8,340 $18 $39
Infliximab infusion (Remicade) 2,170 $26 $115
Blood draw (venipuncture) 881 $8 $9
Infusion, normal saline solution, 250 cc 832 $0 $1
Sed rate test (inflammation marker) 665 $3 $5
Blood creatinine level 623 $5 $10
Urea nitrogen level to assess kidney function, quantitative 616 $4 $8
Complete blood count (CBC) with differential 589 $8 $16
Liver function blood test panel 576 $8 $16
Office visit, established patient (20-29 min) 500 $60 $150
Office visit, established patient (30-39 min) 309 $95 $218
Calcium level, total 252 $5 $10
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less 252 $45 $208
Administration of chemotherapy into vein, 1 hour or less 163 $87 $411
Drug injection, under skin or into muscle 150 $10 $42
Vitamin D level test 119 $29 $59
New patient office visit (45-59 min) 77 $107 $333
Administration of chemotherapy into vein, each additional hour 70 $20 $89
Office visit, established patient (10-19 min) 58 $41 $117
Uric acid level test 45 $4 $9
Rheumatoid factor level 45 $6 $11
Bilirubin level, direct 38 $5 $10
Creatine kinase (cardiac enzyme) level, total 20 $6 $13
Bone density scan (DEXA) 18 $36 $116
Chest X-ray, 2 views 14 $24 $96
Comprehensive metabolic blood panel 14 $10 $21
Parathyroid hormone level test 13 $40 $83
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
31.7% high complexity
62.4% medium
6.0% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$1,958
Total received (2018-2024)
Avg $326/year across 6 years
Bottom 32% in FL for rheumatology
20
Companies
107
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,775 (90.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$183 (9.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$767
2023
$826
2021
$85
2020
$51
2019
$35
2018
$194

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$418
Janssen Biotech, Inc.
$378
UCB, Inc.
$276
ABBVIE INC.
$189
Mallinckrodt Hospital Products Inc.
$119
GENZYME CORPORATION
$96
Novartis Pharmaceuticals Corporation
$92
GlaxoSmithKline, LLC.
$80
Genentech USA, Inc.
$51
Aurinia Pharma U.S., Inc.
$39
Lilly USA, LLC
$33
Sandoz Inc.
$32
PFIZER INC.
$29
E.R. Squibb & Sons, L.L.C.
$28
Kyowa Kirin, Inc.
$23
AstraZeneca Pharmaceuticals LP
$20
Boehringer Ingelheim Pharmaceuticals, Inc.
$19
Horizon Therapeutics plc
$18
AbbVie, Inc.
$11
Janssen Pharmaceuticals, Inc
$7
Top 3 companies account for 54.7% of total payments
Associated products mentioned in payments ›
ACTHAR · Actemra · BENLYSTA · COSENTYX · Cimzia · Crysvita · EVENITY · Enbrel · HUMIRA · HYRIMOZ · INFLECTRA · KEVZARA · KRYSTEXXA · LUPKYNIS · ORENCIA · REMICADE · RINVOQ · Rinvoq · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · TALTZ · TAVNEOS · TREMFYA · XELJANZ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (91%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $2 per 100 Medicare services performed
Looking for a rheumatology specialist in Weston?
Compare rheumatologists in the Weston area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
86
Per 100K population
4.4
County median income
$74,534
Nearest hospital
CLEVELAND CLINIC HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Pancorbo is a mixed practice specialist, with above-average Medicare volume (top 27% in FL), with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Pancorbo experienced with tocilizumab injection (actemra)?
Based on Medicare claims data, Dr. Pancorbo performed 48,480 tocilizumab injection (actemra) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Pancorbo receive payments from pharmaceutical companies?
Yes. Dr. Pancorbo received a total of $1,958 from 20 companies across 107 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Pancorbo's costs compare to other rheumatologists in Weston?
Dr. Pancorbo's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Pancorbo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →